1 Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis

- 2 Ryan Marsh ^a, Helen Gavillet ^a, Liam Hanson ^{a,b}, Christabella Ng ^{c,d}, Mandisa Mitchell-Whyte ^e, Giles Major ^c,
- 3 Alan R Smyth ^{c,d}, Damian Rivett ^b, Christopher van der Gast ^{a,f *}
- 4
- 5 ^a Department of Life Sciences, Manchester Metropolitan University, UK
- 6 ^b Department of Natural Sciences, Manchester Metropolitan University, UK
- 7 ^c School of Medicine, University of Nottingham, UK
- 8 ^dNIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University
- 9 of Nottingham, Nottingham, UK
- 10 ° Wolfson CF Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK
- ¹¹ ^fDepartment of Respiratory Medicine, Salford Royal NHS Foundation Trust, Salford, UK
- 12
- 13 *Correspondence to Professor Chris van der Gast, Department of Life Sciences, Faculty of Science and
- 14 Engineering, John Dalton Building, Chester Street, Manchester, M1 5GD, UK; C.vanderGast@mmu.ac.uk
- 15
- 16 Keywords: gut microbiome, gut microbiota, dysbiosis, MRI, antibiotics, intestinal physiology
- 17
- 18

19 Highlights

- 20 Faecal microbiota significantly differs between pwCF and healthy controls
- Key SCFA producers contributed to microbiota dissimilarity between groups
- Pulmonary antibiotic treatment heavily impacted gut microbiota
- 23 Intestinal physiology and transit impacted satellite microbiota composition

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 Abstract

Background: Most people with cystic fibrosis (pwCF) suffer from gastrointestinal symptoms and are at risk of gut complications. Gut microbiota dysbiosis is apparent within the CF population across all age groups, with evidence linking dysbiosis to intestinal inflammation and other markers of health. This pilot study aimed to investigate the potential relationships between the gut microbiota and gastrointestinal physiology, transit, and health.

30

Study Design: Faecal samples from 10 pwCF and matched controls were subject to 16S rRNA sequencing.
 Results were combined with clinical metadata and MRI metrics of gut function to investigate relationships.

33

Results: pwCF had significantly reduced microbiota diversity compared to controls. Microbiota compositions were significantly different, suggesting remodelling of core and rarer satellite taxa in CF. Dissimilarity between groups was driven by a variety of taxa, including *Escherichia coli*, *Bacteroides spp., Clostridium spp.*, and *Faecalibacterium prausnitzii*. The core taxa were explained primarily by CF disease, whilst the satellite taxa were associated with pulmonary antibiotic usage, CF disease, and gut function metrics. Species-specific ordination biplots revealed relationships between taxa and the clinical or MRI-based variables observed.

40

41 *Conclusions*: Alterations in gut function and transit resultant of CF disease are associated with the gut 42 microbiota composition, notably the satellite taxa. Delayed transit in the small intestine might allow for the 43 expansion of satellite taxa resulting in potential downstream consequences for core community function in the 44 colon.

45 1. Introduction

46 Cystic fibrosis (CF) associated respiratory infections are the major cause of disease morbidity and mortality.
47 However, a number of gastrointestinal (GI) problems may also arise, limiting the quality of life, including
48 meconium ileus at birth, distal intestinal obstruction syndrome, small intestinal bacterial overgrowth (SIBO),
49 increased risk of malignancy, and intestinal inflammation [1,2]. It is therefore unsurprising that people with CF
50 experience persistent GI symptoms [3,4] with "how can we relieve gastrointestinal symptoms in people with
51 CF?" a top priority question for research [5].

52

53 Microbial dysbiosis at the site of the GI tract in CF patients has been described, with changes evident from 54 birth through to adulthood [6-8]. Moreover, the extent of this divergence from healthy microbiota, initially due 55 to loss of cystic fibrosis transmembrane conductance regulator (CFTR) function [9], is further compounded by 56 routine treatment with broad spectrum antibiotics [10]. The reshaping of the gut microbiota may have functional 57 consequences that could further impact on patients. These include the reduction of taxa associated with the 58 production of short-chain fatty acids (SCFAs) which play key roles in modulating local inflammatory responses 59 and promoting gut epithelial barrier integrity [11–13]. Furthermore, studies of microbiota dysbiosis in CF have 60 demonstrated its relationship with intestinal inflammation [14], intestinal lesions [15], and increased gene 61 expression relating to intestinal cancers [16]. Whilst many of these clinical parameters have ties to gut 62 microbiota changes, they remain understudied exclusively past childhood despite advances in less invasive 63 approaches to investigate CF gut physiology and function [17]. Our group has recently published on the use 64 of magnetic resonance imaging (MRI) to assess gut transit time, along with other parameters, in adolescents 65 and adults [18].

66

In this pilot study, we linked those MRI physiology metrics and clinical metadata directly to high-throughput
amplicon sequencing data identifying constituent members of the gut microbiota, to explore the relationships
between microbial dysbiosis, intestinal function and clinical state.

70 2. Materials and methods

71 2.1. Study participants and design

72 Twelve people with CF, homozygous for p.Phe508del along with 12 healthy controls, matched by age and 73 gender, were recruited from Nottingham University Hospitals NHS Trust. Participants were asked to provide 74 stool samples when attending for MRI scanning, with the study design and MRI protocols described previously 75 [18]. A patient clinical features were also recorded upon visitation (Table 1), including a three-day food diary 76 preceding sample collection (Table S1). Further descriptive statistics of the study population can be found in 77 the Supplementary Materials, including MRI metrics (Table S2), and summary statistics on diet (Tables S3-78 S6). Faecal samples were only obtained from ten individuals in each group. Written informed consent, or 79 parental consent and assent for paediatric participants, was obtained from all participants. Study approval was 80 obtained from the West Midlands Coventry and Warwickshire Research Ethics Committee (18/WM/0242). All 81 stool samples obtained were immediately stored at -80°C prior to DNA extraction to reduce changes before 82 downstream community analysis [19].

83

84 2.2. Targeted amplicon sequencing

85 DNA from dead or damaged cells, as well as extracellular DNA was excluded from analysis via cross-linking 86 with propidium monoazide (PMA) prior to DNA extraction, as previously described [20]. Next, cellular pellets 87 resuspended in PBS were loaded into the ZYMO Quick-DNA Fecal/Soil Microbe Miniprep Kit (Cambridge 88 Bioscience, Cambridge, UK) as per manufacturer's instructions, with the following amendments: ZR 89 BashingBead Lysis Tubes were replaced with standard 1.5 mL Eppendorf tubes loaded with ZYMO Beads for 90 mechanical homogenisation with the use of a Retsch Mixer Mill MM 400 (Retsch, Haan, Germany), Samples 91 were homogenised for 2 minutes at 17.5/s frequency. Following DNA extraction, approximately 20 ng of 92 template DNA was then amplified using Q5 high-fidelity DNA polymerase (New England Biolabs, Hitchin, UK) 93 using a paired-end sequencing approach targeting the bacterial 16S rRNA gene region (V4-V5). Primers and 94 PCR conditions can be found in the Supplementary Materials. Pooled barcoded amplicon libraries were 95 sequenced on the Illumina MiSeq platform (V3 Chemistry).

96

97 2.3. Sequence processing and analysis

Sequence processing and data analysis were initially carried out in R (Version 4.0.1), utilising the package
DADA2 [21]. The full protocol is detailed in the Supplementary Materials. Raw sequence data reported in this

study has been deposited in the European Nucleotide Archive under the study accession numberPRJEB44071.

102

103 2.4. Faecal Calprotectin

Stool was extracted for downstream assays using the ScheBo® Master Quick-Prep (ScheBo Biotech, Giessen, Germany), according to the manufacturer instructions. Faecal calprotectin was analysed using the Bühlmann fCAL ELISA (Bühlmann Laboratories Aktiengesellschaft, Schonenbuch, Switzerland), according to the manufacturer's protocol.

108

109 2.5. Statistical Analysis

110 Regression analysis, including calculated coefficients of determination (*r*²), degrees of freedom (df), *F*-statistic 111 and significance values (*P*) were calculated using XLSTAT v2021.1.1 (Addinsoft, Paris, France). Fisher's alpha 112 index of diversity and the Bray-Curtis index of similarity were calculated using PAST v3.21 [22]. Significant 113 differences in microbiota diversity were determined using Kruskal-Wallis performed using XLSTAT. Analysis 114 of similarities (ANOSIM) with Bonferroni correction was used to test for significance in microbiota composition 115 and was performed in PAST. Similarity of percentages (SIMPER) analysis, to determine which taxa contributed 116 most to compositional differences between groups, was performed in PAST.

117

118 Redundancy analysis (RDA), was performed in CANOCO v5 [23]. Following the determination of clinical 119 variables significantly explanatory for microbiome composition, RDA biplots with these variables were plotted in PAST v3.21. Statistical significance for all tests was deemed at the $p \le 0.05$ level. Supplementary 120 121 information, including metadata, available at figshare.com under are 122 https://doi.org/10.6084/m9.figshare.15073797.v1 and https://doi.org/10.6084/m9.figshare.15073899.v1

									Antibiotic Usag		Isage	3
Study I.D	Sex	Age (Years)	Group	Pancreatic Status	Calprotectin (µg/g)	FEV1%	BMI	Р	Α	М	β	S
365	М	12-16	CF	PI	4.22	87	16.18	-	-	-	+	-
431	Μ	12-16	HC	PS	2.44	-	17.95	-	-	-	-	-
128	Μ	12-16	CF	PI	27.59	97	17.72	+	-	-	-	-
296*	Μ	12-16	HC	PS	-	-	23.44	-	-	-	-	-
643	Μ	12-16	CF	PI	9.77	90	21.83	-	-	+	-	-
159	Μ	12-16	HC	PS	2.72	-	23.49	-	-	-	-	-
297	Μ	12-16	CF	PI	27.61	126	20.83	-	-	-	-	-
947*	Μ	12-16	HC	PS	-	-	20.94	-	-	-	-	-
617	F	12-16	CF	PI	21.15	72	18.42	-	-	+	+	+
964	F	12-16	HC	PS	12.71	-	19.15	-	-	-	-	-
167	Μ	17-21	CF	PI	7.37	99	20.63	-	-	-	-	-
673	Μ	17-21	HC	PS	0.94	-	20.34	-	-	-	-	-
279	F	17-21	CF	PI	27.32	66	20.87	-	-	+	-	-
205	F	17-21	HC	PS	3.84	-	31.91	-	-	-	-	-
596	F	17-21	CF	PI	14.05	61	21.91	-	-	+	-	-
152	F	17-21	HC	PS	4.22	-	21.26	-	-	-	-	-
610*	Μ	23-27	CF	PI	-	66	18.64	-	+	+	-	-
548	Μ	23-27	HC	PS	3.56	-	24.49	-	-	-	-	-
619*	F	23-27	CF	PI	-	60	19.27	-	-	-	-	-
501	F	23-27	HC	PS	7.19	-	28.66	-	-	-	-	-
259	М	28-32	CF	PI	28.30	61	20.21	-	-	+	+	-
986	М	28-32	HC	PS	4.96	-	22.64	-	-	-	-	-
681	F	33-37	CF	PI	11.79	88	21.71	+	-	+	-	-
749	F	33-37	HC	PS	3.00	-	19.57	-	-	-	-	-

124 Subjects marked with an asterisk* indicate those who failed to produce a stool sample for subsequent metagenomic and metabolomic analysis and thus were excluded from downstream analyses. All


125 participants with CF had the gene mutation p.Phe508del/p.Phe508del, with pancreatic insufficiency but no CF-related diabetes. For antibiotic usage, '+' indicates routine administration of the given antibiotic

126 class prior to sampling. Abbreviations: FEV1 – Percent predicted forced expiratory volume in 1 second, BMI – Body mass index, P – Polymyxin, A – Aminoglycoside, M – Macrolide, β – β-lactam, S –

127 Sulfonamide. Asterisks denote participants who did not provide any stool samples upon visitation, and thus were excluded from downstream microbiota analysis.

3. Results 128

129 For both healthy control and CF groups, bacterial taxa were partitioned into core or satellite based on their 130 prevalence and relative abundance as depicted in (Fig. 1). Within the healthy control group, 30 taxa were core 131 constituting 60.5 % of the total abundance, with the remainder accounted for by 386 satellite taxa. In the CF group, 22 core taxa represented 34.7 % of the abundance, with 323 satellite taxa constituting the remainder. 132 Core taxa are listed in Table S7. The whole, core, and satellite microbiota demonstrated similar patterns in 133 134 diversity, whereby there was significantly reduced diversity in the CF group (Fig. 2A, Table S8).




135 136 Figure 1 Distribution and abundance of bacterial taxa across different sample groups. (A) Healthy control. (B) Cystic fibrosis. Given is the percentage number of patient stool samples each bacterial taxon was observed to 137 be distributed across, plotted against the mean percentage abundance across those samples. Core taxa are 138 139 defined as those that fall within the upper quartile of distribution (orange circles), and satellite taxa (grey circles) 140 defined as those that do not, separated by the red vertical line at 75% distribution. Distribution-abundance 141 142 0.0001. Core taxa are listed in Table S7.

143

144 Within-group core microbiota similarity was higher within the healthy control group, with a mean similarity (± 145 SD) of 0.60 \pm 0.08 compared to 0.40 \pm 0.11 for the CF group (Fig. 2B). As expected, satellite taxa similarity 146 within groups was much lower than for the core but was also significantly reduced in CF compared to controls, 147 at 0.35 ± 0.08 and 0.21 ± 0.09 for the healthy control and CF group respectively. ANOSIM testing determined 148 the whole microbiota, core, and satellite taxa of the CF group were significantly different in composition 149 compared to healthy controls (Fig. 2B, Table S9). SIMPER analysis was implemented to reveal which taxa

- were responsible for driving this dissimilarity (Table 2). Of the taxa contributing to > 50% of the differences
- 151 between healthy control and CF groups, those within the genus Bacteroides were represented most.
- 152 Escherichia coli contributed most towards the differences between groups, despite satellite status, followed by
- 153 Bacteroides sp. (OTU 3), Clostridium sp. (OTU 5), Faecalibacterium prausnitzii, and Bacteroides fragilis.



154

Figure 2 Microbiome diversity and similarity compared across healthy controls and cystic fibrosis samples. 155 156 Whole microbiota (black plots) and partitioned data into core (orange plots) and satellite taxa (grey plots) are 157 given. (A) Differences in Fisher's alpha index of diversity between healthy controls and cystic fibrosis samples. 158 Black circles indicate individual patient data. Error bars represent 1.5 times inter-quartile range (IQR). Asterisks 159 between groups denote a significant difference in diversity following use of Kruskal-Wallis tests (P < 0.001). 160 Summary statistics are provided in Table S8. (B) Microbiome variation measured within and between sampling 161 groups, utilising the Bray-Curtis index of similarity. Error bars represent standard deviation of the mean. 162 Asterisks indicate significant differences between sampling groups following the use of one-way ANOSIM testing (P < 0.001). Summary statistics are provided in Table S9. 163

164 **Table 2** Similarity of percentage (SIMPER) analysis of microbiota dissimilarity (Bray-Curtis) between Healthy

165 Control (HC) and Cystic Fibrosis (CF) stool samples.

	%Relative	abundance				
Таха	Mean HC Mean CF		Av. Dissimilarity	% Contribution	Cumulative %	
Escherichia coli	1.84	9.54	4.72	6.39	6.39	
Bacteroides 3	3.84	4.69	3.36	4.55	10.94	
Clostridium 5	0.77	6.44	3.09	4.18	15.13	
Faecalibacterium prausnitzii	8.56	2.95	2.99	4.05	19.18	
Bacteroides fragilis	1.02	5.29	2.75	3.73	22.90	
Bacteroides dorei	3.32	4.31	2.52	3.42	26.32	
Eubacterium rectale	5.03	1.35	2.18	2.95	29.27	
Romboutsia timonensis	1.24	3.95	2.15	2.91	32.18	
Bacteroides uniformis	2.72	4.09	1.62	2.20	34.38	
Dialister invisus	1.00	3.45	1.61	2.19	36.57	
Bacteroides vulgatus	2.37	2.14	1.56	2.11	38.68	
Ruminococcus bromii	2.69	0.42	1.24	1.68	40.36	
Alistipes putredinis	2.08	0.06	1.02	1.38	41.74	
Bacteroides coprocola	1.56	0.92	1.01	1.37	43.11	
Fusicatenibacter saccharivorans	2.62	0.8	1.00	1.36	44.47	
Streptococcus 18	0.26	1.95	0.88	1.19	45.66	
Blautia luti	2.93	2.31	0.86	1.16	46.82	
Oscillibacter ruminantium	1.90	0.27	0.84	1.14	47.96	
Clostridium perfringens	0.00	1.58	0.79	1.07	49.03	
Parabacteroides distasonis	1.38	1.85	0.77	1.05	50.08	

Taxa identified as core are highlighted in orange, whereas satellite taxa are highlighted in grey. Mean relative abundance (%) is also provided for each group. Percentage contribution is the mean contribution divided by the mean dissimilarity across samples (73.79%).
Cumulative percent does not equal 100% as the list is not exhaustive. Given the sequencing length of 16S gene regions, taxon identification should be considered putative.

170

Redundancy analysis (RDA) was used to relate variability in microbiota composition to associated MRI metrics and clinical factors (Table 3). Pulmonary antibiotics and CF disease significantly explained the most variance across the whole and satellite microbiota. Measurements of intestinal transit and function contributed to the whole microbiota variance, albeit to a lesser extent, with variation in OCTT and SWBC also contributing to satellite taxa variance alongside faecal calprotectin levels. In the core taxa analysis, the presence of CF disease was the dominant factor in significantly explaining the compositional variability, followed by sex and body mass index (BMI).


	Microbiota			Core taxa			Satellite taxa		
	Var. Exp (%)	pseudo- <i>F</i>	P (adj)	Var. Exp (%)	pseudo- <i>F</i>	P (adj)	Var. Exp (%)	pseudo- <i>F</i>	P (adj)
Antibiotics	21.5	5.4	0.002				27.1	7.3	0.002
BMI				7.0	2.0	0.042			
Calprotectin							5.9	1.8	0.050
CF Disease	10.9	2.2	0.002	28.9	7.3	0.002	10.3	2.1	0.006
Colon Fasting Vol.	7.5	2.0	0.016						
OCTT	7.4	2.1	0.012				6.7	1.9	0.046
SBWC	5.6	1.7	0.048				7.2	2.4	0.048
Sex				7.9	2.1	0.010			
Total	52.9			43.8			57.2		

179 Table 3 Redundancy analysis to explain percent variation in whole microbiota, core taxa and satellite taxa between all subjects from significant clinical variables 180 measured.

Var. Exp (%) represents the percentage of the microbiota variation explained by a given parameter within the redundancy analysis model. P (adj) is the adjusted significance value following false discovery

181 182 183 rate correction. Antibiotics is the presence/absence of recurrent antibiotic regimes for a given patient. BMI – Body mass index, Colon Fasting Vol – Colon volume at baseline corrected for body surface area, OCTT – Oro-caecal transit time, Antibiotics, SBWC – Small bowel water content corrected for body surface area.

184 A species redundancy analysis biplot (RDA) was constructed to investigate how significant clinical variables 185 from the whole microbiota direct ordination approach explained the relative abundance of taxa from the 186 SIMPER analysis (Fig. 3). Certain taxa grouped away from many of the significant clinical variables shown in 187 a similar manner. This effect was most pronounced for F. prausnitzii, Eubacterium rectale and Ruminoccocus bromii. A combination of clinical factors, including CF disease, increased fasting colonic volume, increased 188 189 SBWC and prolonged OCTT, explained the variance observed in relative E. coli abundance, whilst a more modest effect was observed towards Streptococcus sp. (OTU 18), Dialister invisus, Clostridium perfringens 190 191 and Romboutsia timonensis. Species of Bacteroides, which was the most common genus within the top-192 contributing SIMPER analysis, were explained by the clinical variables to high variability.



194 Fig. 3 Redundancy analysis species biplots for whole microbiota. The 20 taxa contributing most to the 195 dissimilarity (cumulatively > 50%) between healthy and cystic fibrosis groups from the SIMPER analysis (Table 196 2) are shown independently of the total number of ASVs identified (345). Orange circles represent core taxa 197 within the CF group, whilst grey circles denote satellite taxa. Biplot lines depict clinical variables that 198 significantly account for the total variation in taxa relative abundance within the whole microbiota analysis at 199 the $p \le 0.05$ level as seen in Table 3, with species plots indicating the strength of explanation provided by the 200 given clinical variables. 'OCTT' - Oro-caecal transit time, 'SBWC' - Small bowel water content corrected for 201 body surface area, Colon Fasting Volume corrected for body surface area, CF disease. The percentage of 202 microbiome variation explained by each axis is given in parentheses.

203 4. Discussion

204 In this pilot study, we investigated the relationships between clinical factors, MRI markers of GI function and 205 the composition of faecal bacterial microbiota. We have shown that it is possible to partition the gut microbiota 206 into core and satellite taxa to investigate potential community functions and relationships, with the notion that 207 the core constituents contribute to the majority of functionality exhibited by the community [20,24]. As to be 208 expected, the core taxa made up most of the abundance within the healthy control group. Whilst many taxa 209 were also commonly represented in the CF group, the latter was dominated in abundance by the satellite taxa. Our findings of reduced diversity across the whole, core, and satellite microbiota are in agreement with 210 211 previous findings described within the CF gut [7,8,10]. Along with reduced within group similarity in CF 212 compared to healthy controls across all microbiota partitions, this suggests a perturbed community harbouring 213 greater instability, less subsequent resilience, and inherent challenges to the colonisation and establishment 214 of normal commensals. CF associated factors such as varied antibiotic usage will contribute to this reduced 215 similarity, further augmented by the wide age range of pwCF within this study and variation across lifestyle factors. The combination of the aforementioned may elicit stochastic community disruption and increased inter-216 217 individual variation as observed across other mammalian microbiomes [25].

218

219 At the surface, a reduction in the number of taxa labelled as core within the CF group hinted at perturbation 220 and restructuring, further evidenced by the occurrence of taxa exclusively core to this group. This included 221 species of Streptococcus, Pseudomonas, Veillonella, and Enterococcus, all of which were significantly more 222 abundant in the CF group (Table S7), and of which are implicated in both CF lung and gut microbiomes 223 [8,9,24,26–28]. The concept of the "gut-lung axis" in CF arises from the direct translocation of the respiratory 224 microbiota from sputum swallowing to the gut [29], but also the emergence of species in the gut prior to the 225 respiratory environment [27]. This apparent bidirectionality is further supported by the administration of oral 226 probiotics to decrease pulmonary exacerbations in CF [30]. Aside from sputum swallowing, the increase in 227 Streptococcus and Veillonella here could reflect an increased availability of simple carbohydrates from the 228 observed dysmotility of the gut [18]. Streptococci are well equipped with numerous genes for rapid 229 carbohydrate degradation in an environment usually fluctuating in substrate availability, with fermentation-230 derived lactic acid supporting the expansion of Veillonella species in the small intestine [31].

E. coli contributed most to the dissimilarity between healthy and CF groups despite maintaining satellite status throughout both the healthy and CF groups, seemingly resultant of the wide age range of our study participants, of which the higher relative abundances were observed in the younger adolescent patients (Table 2). In

234 childhood studies, a significantly higher relative abundance of Proteobacteria is often reported in relation to 235 dysbiosis, with E. coli abundance associating with poor growth outcomes and intestinal inflammation [32-34]. 236 Other notable taxa contributing to the dissimilarity observed between groups encompassed a variety of key 237 species associated with SCFA production in the colon. This included F. prausnitizii and E. rectale, both of 238 which were significantly decreased in abundance within the CF group, but also R. bromii and B. luti. These 239 taxa have all been previously reported to decrease in the CF gut [8,26,35] alongside other inflammatory 240 conditions [36]. There were also notable contributions to the dissimilarity between groups by Clostridium sp. 241 (OTU 5) (significant difference in relative abundance) and D. invisus (not significant). Clostridium OTU 5 242 aligned exclusively with cluster I members at the 97% threshold, of whom demonstrate the capacity to generate 243 lactate, acetate, propionate, and butyrate via carbohydrate fermentation [37], whilst D. invisus is an 244 intermediary fermenter capable of both acetate and propionate production. This may lend support to the theory 245 that alternate species can retain some functional redundancy in the presence of perturbation to the local 246 community in the CF gut [38].

247

248 Variance across the whole microbiota and satellite taxa was significantly explained by the use of antibiotics 249 (Table 3), of which most pwCF are administered on a routine basis to supress lung infection [39]. The 250 occurrence of both OCTT and SBWC accounting for significant explanation in both the whole microbiota and 251 satellite, but not core taxa analysis, underpins the strong impact of gut physiology and transit on the microbiota 252 in CF. Faecal calprotectin also explained the variance across the satellite taxa, and has been associated with 253 increased abundances of Escherichia, Streptococcus, Staphylococcus and Veillonella, of which contained 254 satellite species significantly increased in our CF group [26,40]. Acidaminococcus sp. have also associated 255 with increased faecal calprotectin levels [28], with Acidaminococcus intestinii another constituent of the CF 256 satellite microbiota that was not present in healthy controls (data not shown). The core taxa was only largely 257 explained by the presence of CF disease itself, perhaps relating to the direct disruption of CFTR function which 258 alone can influence changes in the microbiome [40].

259

Perhaps unsurprisingly, the species ordination biplots of the taxa from SIMPER analysis demonstrated clustering of the key SCFA producers mentioned previously away from the significant disease-associated clinical factors, with antibiotic usage and transit metrics previously shown to reduce the abundance of such taxa [14,41]. Similarly affected were taxa from genera that are associated with better outcomes in other

similarly pro-inflammatory intestinal environments, such as Crohn's disease or ulcerative colitis, including
 Oscillibacter and Fusicanterbacter [42,43].

266

267 C. perfringens has been associated with disease exacerbation in ulcerative colitis [36], SIBO in the CF mouse 268 small intestine [44] and increased deconjugation of bile salts leading to further fat malabsorption by the host 269 [45]. Here it was completely absent from our healthy control group, whilst in the CF group was found to 270 associate with a variety of CF-induced clinical factors as well as OCTT. Also strongly associating with OCTT 271 and impacted substantially more, was E. coli. Increased bacterial load relates to slower transit within the CF 272 mouse small intestine [45]. Concurrently with the observed increase in SWBC reported prior [18], this in theory 273 allows for the expansion of such facultative anaerobes in the small intestine that could potentially affect 274 downstream community dynamics and functional profiles in the colon, given that PMA treatment was utilised 275 to select for viable living taxa from faecal sampling.

276

Although dietary profiles were similar between groups (Tables S3-6) and did not contribute to significant variation in the microbiota, increased fat intake to meet energy requirements is a staple of the CF diet [46]. The infant gut metagenome demonstrates enrichment of fatty acid degradation genes [32] whilst CF-derived *E. coli* strains exhibit improved utilisation of exogenous glycerol as a growth source [47]. Finally, the genus *Bacteroides*, which has been reported to both increase and decrease within CF disease across different age groups [8,9,14], displayed high variability within the species ordination biplot (Fig. 3), perhaps resultant of the varying antimicrobial susceptibility within the genus [48].

284

285 We acknowledge the small sample size of this pilot study limits the power of specific analyses, with the absence 286 of within-group direct ordination approaches which would have allowed for investigation of CF group antibiotic 287 usage and extra clinical factors such as lung function. However, the principle strength of this study is the 288 valuable insight into the relationships between microbiota composition and intestinal physiology and function in CF. Future studies should encompass larger cohorts in a longitudinal fashion with the combination of both 289 290 lung and faecal microbiota data to elucidate such relationships better, including the impact of pulmonary 291 antibiotic usage on the gut microbiota, and the aptly termed gut-lung axis. Evaluation of associations between 292 the microbiota, physiology and the immune response would also improve our understanding of the 293 mechanisms contributing to GI health in CF. Given their possible beneficial effect on intestinal inflammation 294 [49], the impact of CFTR modulator therapy will provide further insights.

295 5. Conclusion

296 This cross-sectional pilot study has identified relationships between markers of clinical status, gastrointestinal 297 function and bacterial dysbiosis in the CF population. By partitioning the community into core and satellite taxa, 298 we were able to reveal the relative contributions of CF-associated lifestyle factors and elements of intestinal 299 function to these subcommunity compositions, and how specific taxa were affected by these clinical factors. Further, as the first study to combine high-throughput gene amplicon sequencing with non-invasive MRI to 300 301 assess underlying gut pathologies, we demonstrate the potential for future collaborations between 302 gastroenterology and microbiology with larger cohort recruitment to investigate these relationships between 303 gut function and the microbiome further.

- 304
- 305

306 Author Contributions

307 CvdG, AS, GM, and RJM conceived the study. RJM, HG, LH, and MMR performed sample processing and 308 analysis. RJM, DR, and CvdG performed the data and statistical analysis. CN, GM, and AS were responsible 309 for sample collection, clinical care records and documentation. RJM, CN, GM and CvdG verified the underlying 310 data. RJM, DR, and CvdG were responsible for the creation of the original draft of the manuscript. RJM, CN, 311 GM, DR, AS, and CvdG contributed to the development of the final manuscript. CvdG is the guarantor of this 312 work. All authors read and approved the final manuscript.

313

314 Funding

A CF Trust Venture and Innovation Award (VIA 77) awarded to CvdG funded this work. Funding for the Gut Imaging for Function and Transit in CF (GIFT-CF) study was received from the Cystic Fibrosis Trust (VIA 061), Cystic Fibrosis Foundation (Clinical Pilot and Feasibility Award SMYTH18A0-I), and National Institute for Health Research Biomedical Research Centre, Nottingham.

319

320 Declaration of Competing Interest

RJM, HG, LH, DM, and CvdG declare support from the CF Trust. CN and GM report grants and speaker honorarium from Vertex, outside the submitted work. ARS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Novartis and personal fees from Vertex, outside the submitted work. In addition, ARS has a patent issued "Alkyl quinolones as biomarkers of *Pseudomonas aeruginosa* infection and uses thereof".

326 **Acknowledgements**

- 327 We would like to thank Neele Dellschaft, Caroline Hoad, Luca Marciani, and Penny Gowland of the Sir Peter
- 328 Mansfield Imaging Centre, University of Nottingham, who acquired the original MRI data [18]. We would also
- 329 like to thank Nottingham Hospitals Charity, who funded faecal calprotectin assays and the transport of faecal
- 330 samples for downstream analysis.
- 331
- 332

333 References

- De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med 2013;3:a009753. 334 [1]
- Ooi CY, Durie PR. Cystic fibrosis from the gastroenterologist's perspective. Nat Rev Gastroenterol 335 [2] 336 Hepatol 2016;13:175-85.
- 337 [3] Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, et al. Abdominal symptoms in cystic 338 fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One 339 2017:12:e0174463.
- 340 Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, et al. A high prevalence of [4] 341 chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated 342 in other GI disorders. United Eur Gastroenterol J 2019;7:881-8.
- 343 Smith S, Rowbotham N, Davies G, Gathercole K, Collins SJ, Elliott Z, et al. How can we relieve [5] 344 gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open 345 Respir Res 2020;7:e000614.
- 346 [6] Antosca KM, Chernikova DA, Price CE, Ruoff KL, Li K, Guill MF, et al. Altered Stool Microbiota of 347 Infants with Cystic Fibrosis Shows a Reduction in Genera Associated with Immune Programming from 348 Birth. J Bacteriol 2019;201:e00274-19.
- 349 [7] Loman BR, Shrestha CL, Thompson R, Groner JA, Mejias A, Ruoff KL, et al. Age and environmental 350 exposures influence the fecal bacteriome of young children with cystic fibrosis. Pediatr Pulmonol 351 2020;55:1661-70.
- 352 [8] Burke DG, Fouhy F, Harrison MJ, Rea MC, Cotter PD, Sullivan OO, et al. The altered gut microbiota in 353 adults with cystic fibrosis. BMC Microbiol 2017;17:58.
- 354 [9] Vernocchi P, Chierico F Del, Russo A, Majo F, Rossitto M, Valerio M, et al. Gut microbiota signatures 355 in cystic fibrosis: Loss of host CFTR function drives the microbiota enterophenotype. PLoS One 356 2018;13:e0208171.
- [10] Kristensen M. Prevaes SMPJ. Kalkman G. Tramper-Stranders GA. Hasrat R. de Winter- de Groot KM. 357 358 et al. Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic 359 treatment. J Cyst Fibros 2020.
- 360 [11] Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, et al. The Microbiome and 361 Butyrate Regulate Energy Metabolism and Autophagy in the Mammalian Colon. Cell Metab 362 2011;13:517-26.
- Chang P V, Hao L, Offermanns S, Medzhitov R. The microbial metabolite butyrate regulates intestinal 363 [12] 364 macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 2014;111:2247-365 2252.
- 366 [13] Arpaia N, Campbell C, Fan X, Dikiy S, Veeken J van der, DeRoos P, et al. Metabolites produced by 367 commensal bacteria promote peripheral regulatory T cell generation. Nature 2013;504:451-455.
- 368 De Freitas MB, Moreira EAM, Tomio C, Moreno YMF, Daltoe FP, Barbosa E, et al. Altered intestinal [14] microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with 369 370 cystic fibrosis. PLoS One 2018;13:e0198457.
- 371 Flass T, Tong S, Frank DN, Wagner BD, Robertson CE, Kotter CV, et al. Intestinal lesions are [15] 372 associated with altered intestinal microbiome and are more frequent in children and young adults with 373 cystic fibrosis and cirrhosis. PLoS One 2015;10:e0116967.
- 374 Dayama G, Priya S, Niccum DE, Khoruts A, Blekhman R. Interactions between the gut microbiome and [16] 375 host gene regulation in cystic fibrosis. Genome Med 2020;12:12.
- Malagelada C, Bendezú RA, Seguí S, Vitrià J, Merino X, Nieto A, et al. Motor dysfunction of the gut in 376 [17] 377 cvstic fibrosis. Neurogastroenterol Motil 2020:00:e13883.
- 378 Ng C, Dellschaft NS, Hoad CL, Marciani L, Ban L, Prayle AP, et al. Postprandial changes in [18] gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. J Cyst 379 380 Fibros 2020.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262265; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 381 [19] Gorzelak MA, Gill SK, Tasnim N, Ahmadi-Vand Z, Jay M, Gibson DL. Methods for improving human 382 gut microbiome data by reducing variability through sample processing and storage of stool. PLoS One 383 2015:10:e0134802.
- 384 [20] Rogers GB, Cuthbertson L, Hoffman LR, Wing PAC, Pope C, Hooftman DAP, et al. Reducing bias in 385 bacterial community analysis of lower respiratory infections. ISME J 2013;7:697-706.
- 386 [21] Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: High resolution 387 sample inference from Illumina amplicon data. Nat Methods 2016;13:4-5.
- 388 [22] Øyvind Hammer, David A.T. Harper and PDR. PAST: Paleontological Statistics Software Package for 389 Education and Data Analysis, Palaeontol Electron 2001:4:9 p.
- 390 ter Braak C, Smilauer P. CANOCO reference manual and user's guide: software for ordination. Ithaca: [23] 391 Microcomputer Power; 2012.
- 392 Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, Hampton TH, et al. Lung function and [24] 393 microbiota diversity in cystic fibrosis. Microbiome 2020;8:45.
- 394 [25] Zaneveld JR, McMinds R, Thurber RV. Stress and stability: Applying the Anna Karenina principle to 395 animal microbiomes. Nat Microbiol 2017;2:17121.
- Enaud R, Hooks KB, Barre A, Barnetche T, Hubert C, Massot M, et al. Intestinal Inflammation in 396 [26] 397 Children with Cystic Fibrosis Is Associated with Crohn's-Like Microbiota Disturbances. J Clin Med 398 2019;8:645.
- 399 [27] Madan JC, Koestle DC, Stanton BA, Davidson L, Moulton LA, Housman ML, et al. Serial analysis of 400 the gut and respiratory microbiome. MBio 2012;3:e00251-12.
- 401 [28] Coffey MJ, Nielsen S, Wemheuer B, Kaakoush NO, Garg M, Needham B, et al. Gut Microbiota in 402 Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci Rep 2019;9:18593.
- Al-Momani H, Perry A, Stewart CJ, Jones R, Krishnan A, Robertson AG, et al. Microbiological profiles 403 [29] 404 of sputum and gastric juice aspirates in Cystic Fibrosis patients. Sci Rep 2016;6:26985.
- 405 [30] Anderson JL, Miles C, Tierney AC. Effect of probiotics on respiratory, gastrointestinal and nutritional 406 outcomes in patients with cystic fibrosis: A systematic review. J Cyst Fibros 2017;16:186-97.
- 407 [31] Kastl AJ, Terry NA, Wu GD, Albenberg LG. The Structure and Function of the Human Small Intestinal 408 Microbiota: Current Understanding and Future Directions. Cell Mol Gastroenterol Hepatol 2020;9:33-409 45.
- 410 Manor O, Levy R, Pope CE, Hayden HS, Brittnacher MJ, Carr R, et al. Metagenomic evidence for [32] 411 taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic 412 fibrosis. Sci Rep 2016;6:22493.
- 413 [33] Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, et al. Escherichia coli dysbiosis 414 correlates with gastrointestinal dysfunction in children with cystic fibrosis. Clin Infect Dis 2014;58:396-415 9.
- 416 [34] Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, et al. Fecal dysbiosis in infants with 417 cystic fibrosis is associated with early linear growth failure. Nat Med 2020;26:215-21.
- Duytschaever G, Huys G, Bekaert M, Boulanger L, Boeck K De, Vandamme P. Dysbiosis of 418 [35] 419 bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros 420 2013:12:206-15.
- Li KY, Wang JL, Wei JP, Gao SY, Zhang YY, Wang LT, et al. Fecal microbiota in pouchitis and 421 [36] 422 ulcerative colitis. World J Gastroenterol 2016;22:8929-39.
- 423 Rainey FA, Hollen BJ, Small A. Genus I. Clostridium Prazmowski 1880, 23AL. 2nd ed. New York: [37] 424 Springer; 2009.
- 425 [38] Wang Y, Leong LEX, Keating RL, Kanno T, Abell GCJ, Mobegi FM, et al. Opportunistic bacteria confer 426 the ability to ferment prebiotic starch in the adult cystic fibrosis gut. Gut Microbes 2019;10:367-81. [39]
- 427 Elborn JS. Cystic fibrosis. Lancet 2016;388:2519–31. 428 [40] Meeker SM, Mears KS, Sangwan N, Brittnacher MJ, Weiss EJ, Treuting PM, et al. CFTR dysregulation
- 429 drives active selection of the gut microbiome. PLoS Pathog 2020;16:e1008251.
- 430 Roager HM, Hansen LBS, Bahl MI, Frandsen HL, Carvalho V, Gøbel RJ, et al. Colonic transit time is [41] 431 related to bacterial metabolism and mucosal turnover in the gut. Nat Microbiol 2016;1:16093.
- 432 [42] Takeshita K, Mizuno S, Mikami Y, Sujino T, Saigusa K, Matsuoka K, et al. A single species of 433 Clostridium Subcluster XIVa decreased in ulcerative colitis patients. Inflamm Bowel Dis 2016;22:2802-434 10.
- 435 Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, et al. Donor Species Richness [43] 436 Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohn's 437 Colitis 2016;10:387-94.
- Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane 438 [44] 439 conductance regulator null mouse small intestine. Infect Immun 2004;72:6040-9.
- 440 De Lisle RC. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. Am J [45] 441 Physiol - Gastrointest Liver Physiol 2007;293:104-11.
- 442 [46] Collins S. Nutritional management of cystic fibrosis - an update for the 21st century. Paediatr Respir

- 443 Rev 2018;26:4-6.
- 444 [47] Matamouros S, Hayden HS, Hager KR, Brittnacher MJ, Lachance K, Weiss EJ, et al. Adaptation of 445 commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis. 446 Proc Natl Acad Sci U S A 2018;115:1605-10.
- 447 [48] Nagy E, Urbán E, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 448 20 years of experience. Clin Microbiol Infect 2011;17:371-9.
- 449 [49] Tetard C, Mittaine M, Bui S, Beaufils F, Maumus P, Fayon M, et al. Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. J Pediatr Gastroenterol Nutr 450 451 2020;71:778-81.